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Introduction
Acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, is a kind of lymphoid neoplasm. Lymphoid neoplasms have been divided into two major categories: neoplasms derived from B-and T-lineage lymphoid precursors and those derived from mature B, T or NK cells in recent WHO classification [1] . And ALL belongs to the first group which is B/Tprecursor-stage lymphoid cell malignancies that block lymphoid differentiation and drive aberrant cell proliferation and survival. In addition, ALL is the most common leukemia in pediatrics, among which there are up to 80% of leukemia in this group and 20% of leukemia in adults [2] . With the developments in theoretical knowledge and techniques, novel treatments in mounting number such as chemotherapy, steroids, radiation therapy and intensive combined treatments have been adopted for ALL treatment.
Nevertheless, relapse among ALL patients is still the leading problem causing children's death. Despite the high cure rate in children with ALL, patients accounting for 10%-20% are forecasted to relapse and outcomes of salvage therapy have been disappointing and there are only one-third of children survived long-term after recurrences of disease [3] . In addition, the outcomes of adults with ALL are usually markedly worse than those of pediatric ones.
Therefore, novel methods and effective drugs are urgently needed.
Arsenic has been known as one of the toxic metalloids and its oxidized form, arsenic trioxide (As2O3) has been successfully used as a medicine for patients with acute promyelocytic leukemia (APL) via intravenous injection.
However, the anticancer effect of arsenic trioxide has not been proven in solid tumors or other hematologic malignancies [4] . KML001 (NaAsO2, Sodium metaarsenite, KOMINOX), a sodium salt of arsenous acid, is a water-soluble, therefore, orally bioavailable, trivalent arsenical compound. KML001 has shown a potent anticancer effect on various human cancers, including solid tumors such as prostate cancer, ovarian cancer and hematologic malignancy like acute myeloid leukemia (AML) [5] [6] [7] . In addition, its half maximal inhibitory concentration (IC50) has been found much lower than arsenic trioxide in various NHL cell lines, which may make it more suitable for clinical applications [8] .
Based on research of epidemiology [9] [10] and in vitro studies [11] [12] [13] , vitamin D derivatives (VDDs) have been considered as a promising anticancer drug. As one of the most typical VDDs, 1, 25-dihydroxyvitamin D3 has been known to control cell proliferation and differentiation as well as calcium related actions in leukemia cells [14] [15] [16] . However, the side effect of hypercalcemia has limited its clinical application to hematologic malignancies. Doxercalciferol, a low calcemic vitamin D2 derivative with the similar effect as 1, 25-dihydroxyvitamin D3, can be safely given to patients and was investigated in phase II studies of the myelodysplastic syndrome [17] and androgen-independent prostate cancer [18] .
In our study, the antileukemic effect of KML001 on ALL was investigated, which was focused on apoptosis and cell cycle. In addition, the combination effect of KML001 with Doxercalciferol was studied. And here, we provided evidence of synergistic effect of KML001 and Doxercalciferol in ALL cell lines and possible explanations of this synergy.
Materials and methods
Cells and cell culture. Human acute lymphoid leukemia cell line CCRF-CEM and Molt-4 were kindly presented by Dr. YY Lee (Hanyang University, Seoul, Korea). The cells were cultured in tissue flasks or plates in RPMI-1640 medium supplemented with 10% fetal bovine serum (Gibco-BRL, Gaithersburg, MD, USA), 100 U/ml penicillin, 100 µg/ml streptomycin and incubated at 37˚C in a humidified atmosphere with 5% CO2.
Chemicals and antibodies. KML001 was obtained from Komipharm
International (Siheung-Si, Gyeonggi-Do, South Korea). As2O3 was purchased 
Results
The Previous studies have demonstrated that antileukemia activity of KML001
is mainly due to its ability to induce apoptosis and cell cycle arrest via regulation of MAPK and PI3K pathways or telomere shortening [6, 24] . Also, our study showed that KML001 did induce apoptosis both in CCRF-CEM and Molt-4 cell lines. Gene expression of Bcl-xL, Bax, Bcl-2, members of Bcl-2 family, has been known to control the apoptotic machinery [25] . KML001
increased expression of pro-apoptotic protein Bax, and suppressed the expression of anti-apoptotic protein Bcl-xl in both cell lines.
Cdk1/Cyclin B1 complex is one of the pivotal signaling molecules driving cell progression, which is involved in G2/M check point. Down regulation of Cdk1 or Cyclin B1 expression may lead to cell cycle arrest at G2/M phase. In our experiments, constant decreasing expression of Cdk1 in western blot plus flow cytometry results identified that treatment with KML001 induced cell cycle arrest mainly at G2/M phase rather than at G0/G1 phase which was shown in AML research [6] . 
